CTRI/2023/05/053188尚未招募3 期
An Open Label Randomized Study of Low Dose Dasatinib (50 mg OD) vs Standard Dose Dasatinib (100 mg OD) vs Standard Dose Imatinib (400 mg OD) as Upfront Therapy in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) - Chronic Phase (CP)
il0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Treatment-naïve, newly diagnosed adults (>= 18 years of age) with CML-CP, coming to the Department of Hematology after the Ethical approval for the study is granted, and providing informed consent for inclusion in the study, will be included in the study
排除标准
- •a. Blast-crisis disease at diagnosis
- •b. Pregnant female, breastfeeding female, or potential pregnancy
- •c. Serious uncontrolled medical disorders
- •d. Pre-existing renal or hepatic dysfunction
- •e. QTc > 450 msec
- •f. Major bleeding disorder unrelated to CML
- •g. Myocardial infarction <6 months before enrollment
- •h. Congestive heart failure <3 months before enrollment
- •i. Uncontrolled hypertension or cardiac disease
- •j. Previous or concurrent chemotherapy
- •k. Baseline pleural effusion
研究者
相似试验
已完成
3 期
Comparison of dutasteride and finasteride for the treatment of male pattern hair loss in meCTRI/2015/01/005482okmanya Tilak Municipal Medical College General Hospital90
尚未招募
2 期
A Trial Comparing The Efficacy Of Combination Of Low Dose Of Dexmedetomidine And Bupivacaine 0.0625% With Plain Bupivacaine 0.125% In Postoperative Pain Management And Recovery In Abdominal And Lower Limb SurgeriesCTRI/2024/05/068224ayana Sabu
招募中
2 期
A clinical trial of dasatinib vs. nilotinib in children with CP- and AP-CMChronic myeloid leukemiaJPRN-jRCTs041190038Keino Dai65
招募中
3 期
Study of Dato-DXd With or Without Durvalumab Compared With Investigators Choice of Chemotherapy in Combination With Pembrolizumab as first line therapy for Locally Recurrent Inoperable or Metastatic Breast CancerCTRI/2024/04/065629AstraZeneca AB
尚未招募
3 期
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)Breast CancerJPRN-jRCT2061230102Inoguchi Akihiro625